{"denoms":[{"counts":[{"groupId":"BG000","value":"53"},{"groupId":"BG001","value":"49"},{"groupId":"BG002","value":"102"}],"units":"Participants"}],"groups":[{"description":"Participants received bortezomib 1.3 mg/m\\^2 administered as a 3- to 5-second bolus intravenous injection on Days 1, 4, 8, and 11 of a 21-day cycle for a maximum of eight cycles and placebo intravenous infusion on the first day of each 21-day cycle during the blinded treatment phase. At the completion of the 8-cycle treatment phase, participants entered the observation phase until disease progression.","id":"BG000","title":"BORT + P"},{"description":"Participants received bortezomib 1.3 mg/m\\^2 administered as a 3- to 5-second bolus intravenous injection on Days 1, 4, 8, and 11 of a 21-day cycle for a maximum of eight cycles and bevacizumab 15 mg/kg administered by intravenous infusion on the first day of each 21-day cycle during the blinded treatment phase. After completion of 8 cycles, participants could continue to receive bevacizumab as monotherapy until disease progression.","id":"BG001","title":"BORT + BV"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.2","value":"64.9"},{"groupId":"BG001","spread":"9.3","value":"65.6"},{"groupId":"BG002","spread":"9.2","value":"65.2"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"43"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"59"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}]}